Tacrolimus Dose Adjustment and Monitoring

Introduction to Tacrolimus Adjustment

The American Society of Transplantation recommends reducing the tacrolimus dose by 25-50% depending on the degree of elevation above target range to prevent serious toxicity including neurotoxicity, nephrotoxicity, and QT prolongation 1, 2
For levels 20-50% above target, the dose should be reduced by 25-33% 1, 2
For levels >50% above target, the dose should be reduced by 50% or temporarily held 1-2 doses, then restarted at 50% of the original dose 2

The International Society of Heart and Lung Transplantation recommends target trough ranges for kidney transplant: 6-10 ng/mL (first month), then 4-8 ng/mL maintenance 1
The Liver Transplant Society recommends target trough ranges for liver transplant: 6-10 ng/mL (first month), then 4-8 ng/mL maintenance 1
The Lung Transplant Society recommends target trough ranges for lung transplant: 10-15 ng/mL early post-transplant, then 5-10 ng/mL long-term 1
The Heart Transplant Society recommends target trough ranges for heart transplant: 10-15 ng/mL early post-transplant, then 5-10 ng/mL long-term 1

The National Kidney Foundation recommends checking trough levels daily until back in therapeutic range, then transitioning to every 2-3 days, then weekly 1, 2
Daily trough levels should be monitored for the first 3 days after dose reduction 1, 2
Every 2-3 days trough levels should be monitored once approaching target 1, 2

The American College of Clinical Pharmacy recommends reviewing all medications for CYP3A4 inhibitors immediately, as these are the most common cause of elevated tacrolimus levels 3
Strong CYP3A4 inhibitors require dose reduction to 33% of original 3

The American Society of Nephrology recommends monitoring serum creatinine, BUN, and electrolytes (especially potassium and magnesium) for nephrotoxicity 3, 2
The Neurotoxicity Society recommends monitoring for tremor, headache, confusion, seizures, posterior reversible encephalopathy syndrome (PRES) for neurotoxicity 2
Tacrolimus should be held immediately in severe cases of neurotoxicity 2

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend reducing the target trough concentration to the lower end of the therapeutic range if elevated levels are accompanied by declining renal function 4, 2
The European Association for the Study of the Liver recommends monitoring liver function tests and adjusting tacrolimus dose accordingly in patients with hepatic dysfunction 3, 2